Muromonab CD3: A Reappraisal of its Pharmacology and Use as Prophylaxis of Solid Organ Transplant Rejection

Drugs

Volumn 51, Issue 5, 1996, Pages 865-894

  Wilde, Michelle I ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS; MURINAE;

ANTIBODY; AZATHIOPRINE; CD3 ANTIGEN; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; OKT 3; PREDNISONE; THYMOCYTE ANTIBODY;

ASEPTIC MENINGITIS; CHILL; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FEVER; GASTROINTESTINAL DISEASE; GRAFT REJECTION; HEART TRANSPLANTATION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNOGENICITY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TRANSPLANTATION; LIVER TOXICITY; LIVER TRANSPLANTATION; LUNG EDEMA; LYMPHOPROLIFERATIVE DISEASE; NEPHROTOXICITY; PERIPHERAL LYMPHOCYTE; PHARMACOECONOMICS; REVIEW; RISK; SEIZURE; SURVIVAL; T LYMPHOCYTE ACTIVATION; THROMBOSIS;

ANIMALS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MUROMONAB-CD3;

EID: 0029932047     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199651050-00010     Document Type: Review

References (214)

1. Todd PA, Brogden RN, Muromonab CD3: a review of its pharmacology and therapeutic potential. Drugs 1989; 37: 871-99
2. Chatenoud L, Bach J-F. Selective immunosuppression with anti-T cell monoclonal antibodies. Clin Nephrol 1992; 38 Suppl. 1: 53-60
3. Roitt IM. OKT3: immunology, production, purification, and pharmacokinetics. Clin Transpl 1993 Aug; 7 (Pt 2): 367-73
4. Cosimi AB. Current and future application of monoclonal antibodies in clinical immunosuppressive protocols. Clin Transpl 1995 Jun; 9 (Pt 2): 219-26
5. Norman DJ. Mechanisms of action and overview of OKT3. Ther Drug Monit 1995; 17: 615-20
6. Gonçalves LF, Rauber ML, Manfro RC, et al. Fine needle aspiration biopsy in renal transplant patients on prophylactic OKT3 treatment. Transplant Proc 1992 Dec; 24: 3085-6
7. Ouwehand AJ, Baan CC, Groeneveld K, et al. Altered specificity of alloreactive cardiac graft-infiltrating cells by prophylactic treatment with OKT3 or horse antilymphocyte globulin. Transplantation 1993; 55: 154-8
8. Janssen O, Wesselborg S, Kabelitz D. Immunosuppression by OKT3 - induction of programmed cell death (apoptosis) as a possible mechanism of action. Transplantation 1992 Jan; 53: 233-4
9. Magnussen K, Klug B, Moller B. CD3 antigen modulation in T-lymphocytes during OKT3 treatment. Transplant Proc 1994 Jun; 26: 1731
10. Buysmann S, van Diepen FNJ, van Kooyk Y, et al. The influence of OKT3 on expression of lymphocyte adhesion molecules in vitro. Transplant Proc 1994 Dec; 26: 3249-50
11. Buysmann S, Bemelman FJ, Schellekens PT, et al. Activation and increased expression of adhesion molecules on peripheral blood lymphocytes is a mechanism for the immediate lymphocytopenia after administration of OKT3. Blood 1996; 87 (1): 404-11
12. Wong JT, Eylath A, Ghobrial I, et al. The mechanism of anti-CD3 monoclonal antibodies. Mediation of cytolysis by inter-T cell bridging. Transplantation 1990 Oct; 50: 683-9
13. Abramowicz D, Goldman M, De Pauw L, et al. The long-term effects of prophylactic OKT3 monoclonal antibody in cadaver kidney transplantation - a single-center, prospective, randomised study. Transplantation 1992 Sep; 54: 433-7
14. Abramowicz D, Schandene L, Goldman M, et al. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989; 47: 606-8
15. Ellenhorn JDI, Woodle ES, Ghobreal I, et al. Activation of human T cells in vivo following treatment of transplant recipients with OKT3. Transplantation 1990 Oct; 50: 608-12
16. Gaston RS, Deierhoi MH, Patterson T, et al. OKT3 first-dose reaction: association with T-cell subsets and cytokine release. Kidney Int 1991 Jan; 39: 141-8
17. Raasveld MHM, Bemelman FJ, Schellekens PThA, et al. Compliment activation during OKT3 treatment: a possible explanation for respiratory side effects. Kidney Int 1993 May; 43: 1140-9
18. Chatenoud L. Use of CD3 antibodies in transplantation and autoimmune diseases. Transplant Proc 1994 Dec; 26: 3191-3
19. Kreis H. Adverse events associated with OKT3 immunosuppression in the prevention or treatment of allograft rejection. Clin Transpl 1993 Aug; 7 (Pt 2): 431-46
20. Goumy L, Ferran C, Merite S, et al. In vivo anti-CD3-driven cell activation. Cellular source of induced tumour necrosis factor, interleukin-1β, and interleukin 6. Transplantation 1996; 61: 83-7
21. Bloemena E, ten Berge IJM, Surachno J, et al. Kinetics of interleukin 6 during OKT3 treatment in renal allograft recipients. Transplantation 1990 Aug; 50: 330-1
22. Hoffman T, Tripathi AK, Lee YL, et al. Stimulation of human monocytes by anti-CD3 monoclonal antibody: induction of inflammatory mediator release via immobilization of Fc receptor by adsorbed immunoglohulin and T-lymphocytes. Inflammation 1992 Dec; 16: 571-85
23. Woodle ES, Thistlethwaite JR, Jolliffe LK, et al. T-cell activation and lymphokine production induced by antihuman CD3 monoclonal antibodies. Transplant Proc 1991; 23: 81-2
24. Vossen ACTM, Tibbe GJM, Kroos MJ, et al. Fc receptor binding of anti-CD3 monoclonal antibodies is not essential for immunosuppression, but triggers cytokine-related side effects. Eur J Immunol 1995; 25: 1492-6
25. Goldman M, Geacute;rard C, Abramowicz D, et al. Induction of interleukin-6 and interleukin-10 by the OKT3 monoclonal antibody: possible relevance to posttransplant lymphoproliferative disorders. Clin Transpl 1992 Jun; 6: 265-8
26. Swinnen LJ, Fisher RI. OKT3 monoclonal antibodies induce interleukin-6 and interleukin-10: a possible cause ot lymphoproliferative disorders associated with transplantation. Curr Opin Nephrol Hypertension 1993 Jul; 2: 670-8
27. Ferran C, Dy M, Merite S, et al. Reduction of morbidity and cytokine release in anti-CD3 MoAb-treated mice by corticosteroids. Transplantation 1990 Oct; 50: 642-8
28. Chatenoud L, Ferran C, Legendre C, et al. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 1990 Apr; 49: 697-702
29. Chatenoud L, Legendre C, Ferran C, et al. Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome - dosage and kinetics prerequisites. Transplantation 1991 Feb; 51: 334-8
30. Schandené L, Gérard C, Crusiaux A, et al. Interleukin-10 inhibits OKT3-induced cytokine release: in vitro comparison with pentoxifylline. Transplant Proc 1993 Apr; 25 (2 Suppl. 1): 55-6
31. Leimenstoll G, Zabel P, Schroeder P, et al. Suppression of OKT3-induced tumor necrosis factor alpha formation by pentoxifylline in renal transplant recipients. Transplant Proc 1993 Feb; 25 (Pt 1): 561-3
32. Donckier V, Flament V, Gérard C, et al. Modulation of the release of cylokines and reduction of the shock syndrome induced by anti-CD3 monoclonal antibody in mice by interleukin-10. Transplantation 1994 May 27; 57: 1436-9
33. De Vault Jr GA, Kohan DE, Nelson EW, et al. The effects of oral pentoxifylline on the cytokine release syndrome during inductive OKT3. Transplantation 1994 Feb 27; 57: 532-40
34. Alegre M-L, Gastaldello K, Abramowicz D, et al. Evidence that pentoxifylline reduces anti-CD3 monoclonal antibody-induced cytokine release syndrome. Transplantation 1991 Oct; 52: 674-9
35. Carey G, Lisi PJ, Schroeder TJ. The incidence of antibody formation to OKT3 consequent to its use in organ transplantation. Transplantation 1995; 60: 151-8
36. Chatenoud L. Humoral immune response against OKT3. Transplant Proc 1993 Apr; 25 Suppl. 1: 68-73
37. Norman DJ. Antilymphocyte antibodies in the treatment of allograft rejection: targets, mechanisms of action, monitoring, and efficacy. Semin Nephrol 1992; 12: 315-24
38. Kimball JA, Norman DJ, Shield CF, et al. OKT3 antibody response study: comparative testing of human antimouse antibody. Transplant Proc 1993 Apr; 25 Suppl. 1: 74-6
39. O'Connell JB, Bristow MR, Hammond EH, et al. Antimurine antibody to OKT3 in cardiac transplantation: implications for prophylaxis and retreatment of rejection. Transplant Proc 1991 Feb; 23: 1157-9
40. Schroeder TJ, Michael AT, First MR, et al. Variations in serum OKT3 concentration based upon age, sex, transplanted organ, treatment regimen, and anti-OKT3 antibody status. Ther Drug Monit 1994 Aug; 16: 361-7
41. Taylor DO, Bristow MR, O'Connell JB, et al. A prospective, randomized comparison of cyclophosphamide and azathioprine for early rejection prophylaxis after cardiac transplantation: decreased sensitization to OKT3. Transplantation 1994 Sep 27; 58: 645-9
42. Schroeder TJ, First MR, Mansour ME, et al. Antimurine antibody formation following OKT3 therapy. Transplantation 1990 Jan; 49: 48-51
43. Norman DJ, Chatenoud L, Cohen D, et al. Consensus statement regarding OKT3-induced cytokine-release syndrome and human antimouse antibodies. Transplant Proc 1993 Apr; 25 Suppl. 1: 89-92
44. Rohrer RJ, Jenkins RL, Khettry U, et al. Immunohistology of liver allografts in recipients managed with prophylactic OKT3. Transplant Proc 1989; 21: 2249-50
45. Kemnitz J, Cremer J, Schaefers HJ, et al. Some aspects of changed histopathologic appearance of acute rejection in cardiac allografts after prophylactic application of OKT3. J Heart Lung Transplant 1991 May-Jun; 10: 366-72
46. Kaufman C, Zeevi A, Zerbe T, et al. In vitro studies of endomyocardial biopsies from heart transplant recipients on RATG and OKT3 immunoprophylaxis protocols. Transplantation 1989; 48: 621-5
47. Fyfe AI, Harper CM. Anti-thymocyte globulin and OKT3 have opposite effects on adhesion of cardiac transplant recipient mononuclear cells to arterial endothelium [abstract]. Circulation 1993; 44: 1-41
48. Breisblatt WM, Schulman DS, Stein K, et al. Hemodynamic response to OKT3 in orthotopic heart transplant recipients: evidence for reversible myocardial dysfunction. J Heart Lung Transplant 1991 May-Jun; 10: 359-65
49. Robinson ST, Barry JM, Norman DJ. The hemodynamic effects of intraoperative injection of muromonab CD3. Transplantation 1993 Aug; 56: 356-8
50. Stein KL, Ladowski J, Kormos R, et al. The cardiopulmonary response to OKT3 in orthotopic cardiac transplant recipients Chest 1989 Apr; 95: 817-21
51. Beilman GJ, Shield III CF, Hughes JD, et al. The effects of intraoperative administration of OKT3 during renal transplantation. Transplantation 1993 Mar; 55: 490-3
52. Raasveld MHM, Hack CE, ten Berge IJM. Activation of coagulation and fibrinolysis following OKT3 administration to renal transplant recipients: association with distinct mediators. Thromb Haemost 1992 Sep 7; 68: 264-7
53. Abramowicz D, Pradier O, De Pauw L, et al. High-dose glucocorticosteroids increase the procoagulant effects of OKT3. Kidney Int 1994 Dec; 46: 1596-602
54. Pradier O, Marchant A, Abramowicz D, et al. Procoagulant effect of the OKT3 monoclonal antibody: involvement of tumor necrosis factor. Kidney Int 1992 Nov; 42: 1124-9
55. Goldman MH, McGrath G, Freeman M, et al. D-Dimer XDP correlates with fibrinolytic shutdown in renal transplant patients treated with anti-T-cell antibodies. Transplant Proc 1995 Feb; 27: 1094-6
56. Pradier O, Abramowicz D, Capel P, et al. Procoagulant properties of OKT3 at the monocyte level: inhibition by pentoxifylline. Transplant Proc 1993 Apr; 25 Suppl. 1: 39-40
57. Hesse CJ, Heyse P, Stolk BJM, et al. Differences in antibody formation to OKT3 between kidney and heart transplantation recipients. Transplant Proc 1989; 21: 979-80
58. Henell KR, Norman DJ. Monitoring OKT3 treatment: pharmacodynamic and pharmacokinetic measures. Transplant Proc 1993 Apr; 25 Suppl. 1: 83-5
59. Madden RL, Schroeder TJ, Alexander JW, et al. Single dose OKT3: adverse effects, pharmacokinetics, and anti-OKT3 antibody response. Transplant Sci 1994 Sep; 4: 111-4
60. Goldslein G, Fuccello AJ, Norman DJ, et al. OKT3 monoclonal antibody plasma levels during therapy and the subsequent development of host antibodies to OKT3. Transplantation 1986; 42: 507-11
61. Schroeder TJ, First MR, Hurtubise PE, et al. Immunologic monitoring with Orthoclone OKT3 therapy. J Heart Transplant 1989 Sep-Oct; 8: 371-80
62. Norman DJ. The clinical role of OKT3. Cardiol Clin 1990 Feb; 8: 97-105
63. Hesse CJ, Heyse P, Stolk BJM, et al. Immune monitoring of heart transplant patients receiving either one or two cycles of OKT3 prophylaxis - induced anti-idiotypic and anti-isotypic anti-OKT3 antibodies do not prohibit depletion of peripheral T-cells due to second OKT3 treatment. Clin Transpl 1991 Dec; 5 (Part 1): 446-55
64. Goldstein G, Norman DJ, Henell KR, et al. Pharmacokinetic study of Orthoclone OKT3 serum levels during treatment of acute renal allograft rejection. Transplantation 1988; 46: 587-9
65. Bock HA, Gallati H, Zürcher RM, et al. A randomized prospective trial of prophylactic immunosuppression with ATG-Fresenius versus OKT3 after renal transplantation. Transplantation 1995 Mar 27; 59: 830-40
66. McDiarmid SV, Millis M, Terashita G, et al. Low serum OKT3 levels correlate with failure to prevent rejection in orthotopic liver transplant patients. Transplant Proc 1990 Aug; 22: 1774-6
67. Schroeder TJ, Ryckman FC, Hurtubise PE, et al. Immunological monitoring during and following OKT3 therapy in children. Clin Transpl 1991 Apr; 5: 191-6
68. Abramowicz D, Goldman M, Mat O, et al. OKT3 serum levels as a guide for prophylactic therapy: a pilot study in kidney transplant recipients. Transpl Int 1994 Jul; 7: 258-63
69. + lymphocyte depletion with rejection and infection in renal transplants. Transplant Proc 1993 Aug; 25: 2477-8
70. Gebel H, Lebeck LL, Jensik SC, et al. Discordant expression of CD3 and T cell receptor antigens on lymphocytes from patients treated with OKT3. Transplant Proc 1989; 21: 1745-6
71. Shaefer MS, Stratta RJ, Pirruccello SJ, et al. Peripheral CD3 lymphocyte monitoring of liver transplant recipients being treated with OKT3 for rejection or induction immunosuppression [abstract]. Pharmacotherapy 1990; 10 (3): 248
72. Broughan TA, Valenzuela R, Escorcia H, et al. Mouse antibody-coated lymphocytes during OKT3 therapy in liver transplantation. Clin Transpl 1994 Oct; 8: 488-91
73. Ohman M, Koto M, Leathers LK, et al. Multiparameler monitoring of efficacy of OKT3-induced immune suppression in renal allograft recipients [abstract]. Hum Immunol 1993; 37 Suppl. 1: 95
74. Gebel HM, Lebeck LK, Jensik SC, et al. T cells from patients successfully treated with OKT3 do not react with the T-cell receptor antibody. Hum Immunol 1989 Oct; 26: 123-30
75. Hammond EA, Yowell RL, Greenwood J, et al. Prevention of adverse clinical outcome by monitoring of cardiac transplant patients for murine monoclonal CD3 antibody (OKT3) sensitization. Transplantation 1993 May; 55: 1061-3
76. Moore CK, O'Connell JB, Renlund DG, et al. Cardiac allograft cellular rejection during OKT3 prophylaxis in the absence of sensitization. Transplant Proc 1991 Feb; 23: 1055-8
77. Ryckman FC, Schroeder TJ, Pedersen SH, et al. Use of monoclonal antibody immunosuppressive therapy in pediatric renal and liver transplantation. Clin Transplant 1991; 5: 186-90
78. Toyoda M, Galfayan K, Wachs K, et al. Immunologic monitoring of OKT3 induction therapy in cardiac allograft recipients. Clin Transplant 1995; 9: 472-80
79. Wechsler ME, Giardina E-GV, Sciacca RR, et al. Increased early mortality in women undergoing cardiac transplantation. Circulation 1995 Feb 15; 91: 1029-35
80. Troppmann C, Gillingham KJ, Benedetti E, et al. Delayed graft function, acute rejection, and outcome after cadaver renal transplantation: a multivariate analysis. Transplantation 1995 Apr 15; 59: 962-8
81. Howard RJ, Pfaff WW, Brunson ME, et al. Delayed graft function is associated with an increased incidence of occult rejection and results in poorer graft survival. Transplant Proc 1993 Feb; 25 (1 Pt 2): 884
82. Costanzo-Nordin MR, Fisher SG, O'Sullivan EJ, et al. HLA-DR incompatibility predicts heart transplant rejection independent of immunosuppressive prophylaxis. J Heart Lung Transplant 1993 Sep-Oct; 12: 779-89
83. Kerman RH, Sullivan K, Tejani A. Impact of HLA matching, type of crossmatch and immunosuppressive therapy on primary pediatric cadaver renal allograft survival [abstract]. Hum Immunol 1994; 40 Suppl. 1: 17
84. Norman DJ, Kimball JA, Bennett WM, et al. A prospective, double-blind, randomized study of high-versns low-dose OKT3 induction immunosuppression in cadaveric renal transplantation. Transpl Int 1994 Aug; 7: 356-61
85. Norman DJ, Barry JM, Bennett WM, et al. OKT3 for induction immunosuppression in renal transplantation: a comparative study of high versus low doses. Transplant Proc 1991 Feb; 23: 1052-4
86. Alonso-Pulpón L, Serrano-Fiz S, Rubio JA, et al. Efficacy of low-dose OKT3 as cytolytic induction therapy in heart transplantation. J Heart Lung Transplant 1995 Jan/Feb; 14 (1 Pt 1): 136-42
87. Welter HF, Illner W-D, Schleibner S, et al. Pilot study on induction treatment with high-dose OKT3: preliminary observations in kidney transplantation. Transplant Proc 1990 Oct; 22: 2272
88. Hegewald MG, O'Connell JB, Renlund DG, et al. OKT3 monoclonal antibody given for ten versus fourteen days as immunosuppressive prophylaxis in heart transplantation. J Heart Transplant 1989 Jul-Aug; 8: 303-10
89. Kobashigawa JA, Stevenson LW, Brownfield E, et al. Does short-course induction with OKT3 improve outcome after heart transplantation? A randomized trial. J Heart Lung Transplant 1993 Mar-Apr; 12: 205-8
90. Buysmann S, Hack CE, van Diepen FNJ, et al. Administration of OKT3 via continuous infusion attenuates first-dose side-effects. Kidney Int 1995; 48: 1368-9
91. Ortho Biotech Inc. Orthoclone OKT3 prescribing information. New Jersey, USA, 1995
92. Benvenisty AI, Cohen D, Stegall MD, et al. Improved results using OKT3 as induction immunosuppression in renal allograft recipients with delayed graft function. Transplantation 1990 Feb; 49: 321-7
93. Dafoe DC, Bromberg JS, Grossman RA, et al. Renal transplantation despite a positive antiglobulin crossmatch with and without prophylactic OKT3. Transplantation 1991 Apr; 51: 762-8
94. Norman DJ, Kahana L, Stuart Jr FP, et al. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 1993 Jan; 55: 44-50
95. Broyer M, Gagnadoux M-F, Guest G, et al. Prophylactic OKT3 monoclonal antibody versus antilymphocyte globulins: a prospective, randomized study in 148 first cadaver kidney grafts. Transplant Proc 1993 Feb; 25 (Pt 1): 570-1
96. Cole EH, Cattran DC, Farewell VT, et al. A comparison of rabbit antithymocyte serum and OKT3 as prophylaxis against renal allograft rejection. Transplantation 1994 Jan; 57: 60-7
97. Frey DJ, Matas AJ, Gillingham KJ, et al. Sequential therapy - a prospective randomized trial of malg versus OKT3 for prophylactic immunosuppression in cadaver renal allograft recipients. Transplantation 1992 Jul;; 54: 50-6
98. Hanto DW, Jendrisak MD, So SKS, et al. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial. Transplantation 1994 Feb 15; 57: 377-84
99. Steinmuller DR, Hayes JM, Novick AC, et al. Comparison of OKT3 with ALG for prophylaxis for patients with acute renal failure after cadaveric renal transplantation. Transplantation 1991 Jul; 52: 67-71
100. Opelz G. Efficacy of rejection prophylaxis with OKT3 in renal transplantation. Transplantation 1995; 60: 1220-4
101. Vela C, Cristol JP, Chong G, et al. Antilymphocyte globulins versus OKT3 as prophylactic treatment in highly sensitized renal transplant recipients [abstract]. Nephrol Dial Transplant 1993; 8 (9): 1052
102. Knechtle SJ, Pirsch JD, Groshek M, et al. OKT3 vs ALG induction therapy in combined pancreas-kidney transplantation. Transplant Proc 1991 Feb; 23: 1581-2
103. Lefrançois N, Raffaele P, Martinenghi S, et al. Prophylactic polyclonal versus monoclonal antibodies in kidney and pancreas transplantation. Transplant Proc 1990; 22: 632-3
104. Illner W-D, Theodorakis J, Abendroth D, et al. Quadruple-drug induction therapy in combined renal pancreatic transplantation - OKT3 versus ATG. Transplant Proc 1990 Aug; 22: 1586-7
105. Melzer JS, D'Alessandro AM, Kalayoglu M, et al. The use of OKT3 in combined pancreas-kidney allotransplantation. Transplant Proc 1990 Apr; 22: 634-5
106. Cosimi AB, Jenkins RL, Rohrer RJ, et al. A randomized clinical trial of prophylactic OKT3 monoclonal antibody in liver allograft recipients. Arch Surg 1990 Jun; 125: 781-5
107. Farges O, Ericzon B-G, Bresson-Hadni S, et al. A randomized trial of OKT3-based versus cyclosporine-based immunoprophylaxis after liver transplantation: long-term results of a European and Australian multicenter study. Transplantation 1994 Oct 27; 58: 891-8
108. McDiarmid SV, Millis MJ, Terasaki PI. OKT3 prophylaxis in liver transplantation. Dig Dis Sci 1991 Oct; 36: 1418-26
109. McDiarmid SV, Busuttil RW, Levy P, et al. The long-term outcome of OKT3 compared with cyclosporine prophylaxis after liver transplantation. Transplantation 1991 Jul; 52: 91-7
110. Mühlbacher F, Steininger R, Längle F, et al. OKT3 immunoprophylaxis in human liver transplantation. Transplant Proc 1989; 21: 2253-4
111. Pons JA, Bueno F, Parrilla P, et al. Cyclosporine vs OKT3 prophylaxis after orthotopic liver transplantation. Transplant Proc 1993 Apr; 25: 1949
112. Steininger R, Mühlbacher F, Hamilton G, et al. Comparison of CyA, OKT3, and ATG immunoprophylaxis in human liver transplantation. Transplant Proc 1991 Aug; 23: 2269-71
113. Reding R, Vraux H, de Goyet J de V, et al. Monoclonal antibodies in prophylactic immunosuppression after liver transplantation. A randomized controlled trial comparing OKT3 and anti-IL-2 receptor monoclonal antibody LO-Tact-1. Transplantation 1993 Mar; 55: 534-41
114. Millis JM, McDiarmid S, Hiatt JR, et al. Randomized prospective trial of okt3 for early prophylaxis of rejection after liver transplantation. Transplantation 1989; 47: 82-8
115. Sasaki AW, Lee RG, Porayko MK, et al. Accelerated liver allograft rejection during prophylactic immunosuppression with OKT3. Transplantation 1993 Jan; 55: 216-9
116. Mor E, Skerrett D, Manzarbeitia C, et al. Successful use of an enhanced immunosuppressive protocol with plasmapheresis for ABO-incompatible mismatched grafts in liver transplant recipients. Transplantation 1995 Apr 15; 59: 986-90
117. Tokunaga Y, Tanaka K, Fujita S, et al. Living related liver transplantation across ABO blood groups with FK506 and OKT3. Transpl Int 1993 Nov; 6: 313-8
118. 1 in liver transplantation. Transplant Sci 1994; 4 Suppl. 1: S1-8
119. Balk AHMM, Simoons ML, Jutte NHPM, et al. Sequential OKT3 and cyclosporine after heart transplantation. A randomized study with single and cyclic OKT3. Clin Transpl 1991 Aug; 5: 301-5
120. Barr ML, Sanchez JA, Seche LA, et al. Anti-CD3 monoclonal antibody induction therapy. Immunological equivalency with triple-drug therapy in heart transplantation. Circulation 1990 Nov; 82 Suppl. IV: IV-291-4
121. Stapleton DD, Ventura HO, Grundtner SE, et al. Induction immunosuppression with the monoclonal antibody OKT3 after cardiac transplantation. Am J Med Sci 1993 Jul; 306: 16-9
122. Costanzo-Nordin MR, O'Sullivan EJ, Johnson MR, et al. Prospective randomized trial of OKT3 versus horse antithymocyte globulin bused immunosuppressive prophylaxis in heart transplantation. J Heart Transplant 1990 May-Jun; 9: 306-15
123. Griffith BP, Kormos RL, Armitage JM, et al. Comparative trial of immunoprophylaxis with RATG versus OKT3. J Heart Transplant 1990 May-Jun; 9: 301-5
124. Ippoliti G, Negri M, Abelli P, et al. Preoperative prophylactic OKT3 vs RATG. A randomized clinical study in heart transplant patients. Transplant Proc 1991 Aug; 23: 2272-4
125. Kirklin JK, Bourge RC, White-Williams C, et al. Prophylactic therapy for rejection after cardiac transplantation - a compar-ison of rabbit antithymocyte globulin and OKT3. J Thorac Cardiovasc Surg 1990 Apr; 99: 716-24
126. Ladowski JS, Dillon T, Schatzlein MH, et al. Prophylaxis of heart transplant rejection with either antithymocyte globulin-, Minnesota antilymphocyte globulin-, or an OKT3-based protocol. J Cardiovasc Surg 1993 Apr; 34: 135-40
127. Macdonald PS, Mundy J, Keogh AM, et al. A prospective randomized study of prophylactic OKT3 versus equine antithymocyte globulin alter heart transplantation - increased morbidity with OKT3. Transplantation 1993 Jan; 55: 110-6
128. Menkis AH, Powell A-M, Novick RJ, et al. A prospective randomized controlled trial of initial immunosuppression with ALG versus OKT3 in recipients of cardiac allografts. J Heart Lung Transplant 1992 May-Jun; 11: 569-76
129. Renlund DG, O'Connell JB, Gilbert EM, et al. A prospective comparison of murine monoclonal CD-3 OKT3 antibody-based and equine antithymocyte globulin-based rejection prophylaxis in cardiac transplantation decreased rejection and less corticosteroid use with OKT3. Transplantation 1989; 47: 599-605
130. Wollenek G, Laufer G, Laczkovics A, et al. Comparison of a monoclonal anti-T cell antibody vs ATG as prophylaxis after heart transplantation. Transplant Proc 1989; 21: 2499-501
131. van Gelder T, Mulder AH, Balk AHMM, et al. Intragraft monitoring of rejection after prophylactic treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in heart transplant recipients. J Heart Lung Transplant 1995; 14: 346-50
132. Carrier M, Jenicek M, Pelletier LC. Value of monoclonal antibody OKT3 in solid organ transplantation: a meta-analysis. Transplant Proc 1992 Dec; 24: 2586-91
133. Indudhara R, Khauli RB, Menon M. Simultaneous quadruple immunosuppression with cyclosporine induction therapy in high risk renal transplant recipients. J Urol 1994 Aug; 152 (Pt 1): 307-11
134. Schroeder TJ, First MR, Mansour ME, et al. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients. Am J Kidney Dis 1989 Nov; 14 Suppl. 2: 14-8
135. Abramowicz D, Norman DJ, Vereerstraeten P, et al. OKT3 prophylaxis in renal grafts with prolonged cold ischemia times: association with improvement in long-term survival. Kidney Int. In press
136. Cardella CJ, Blake P, Cattran D, et al. Prophylactic OKT3 in renal retransplantation. Transplant Proc 1989 Apr; 21: 3373-4
137. Schroeder TJ, First MR, Gaber AO. Monitoring and management of immunosuppression in paediatric transplant patients. Clin Immunother 1995; 4 (6): 425-44
138. Shaddy RE, Bullock EA, Morwessel NJ, et al. Murine monoclonal CD3 antibody (OKT3)-based early rejection prophylaxis in pediatric heart-transplant. J Heart Lung Transplant 1993 May-Jun; 12: 434-9
139. Brown JW, Turrentine MW, Kesler KA, et al. Triple-drug immunosuppression for heart transplantation in infants and children. J Heart Lung Transplant 1993 Nov-Dec; 12: S265-74
140. Conley SB, al-Uzri A, So S, et al. Prevention of rejection and graft loss with an aggressive quadruple immunosuppresive therapy regimen in children and adolescents. Transplantation 1994 Feb 27; 57: 540-4
141. Bartosh SM, Aronson AJ, Swanson-Pewitt LE, et al. OKT3 induction in pediatric renal transplantation. Pediatr Nephrol 1993 Feb; 7: 45-9
142. McDiarmid SV, Millis MJ, Terasaki P, et al. Induction of immunosuppression in pediatric orthoptopic liver transplantation. Clin Transpl 1991; 5: 174-80
143. Peters TG, Charlton RK, Jones KW, et al. Kidney transplantation in the older patient. J Fla Med Assoc 1994 Aug; 81: 535-8
144. Schroeder TJ, Rossi SJ, First MR. OKT3 monoclonal antibody therapy. International Consensus Conference on Immunosuppressive Drugs. 1995 5 May
145. Shield III CF. Consequences of anti-OKT3 antibody development: OKT3 reuse and long-term graft survival. Transplant Proc 1993 Apr; 25 Suppl. 1: 81-2
146. Hayes JM. The immunobiology and clinical use of current immunosuppressive therapy for renal transplantation. J Urol 1993 Mar; 149: 437-48
147. Niaudet P, Jean G, Broyer M, et al. Anti-OKT3 response following prophylactic treatment in paediatric kidney transplant recipients. Pediatr Nephrol 1993 Jun; 7: 263-7
148. Mozes MF, Venkat KK, Kupin W, et al. Is the routine use of induction immunosuppression with ALG or OKT3 justified in cadaveric renal transplantation? Transplant Proc 1993 Feb: 25 (Pt 1): 575-6
149. Rossi SJ, Schroeder TJ, Hariharan S. Prevention and management of the adverse effects associated with immunosuppressive therapy. Drug Saf 1993 Aug; 9: 104-31
150. Barclay PG, Allen RDM, Stewart JH, et al. Costs of immunosuppressive therapies used in renal transplantation. Transplant Proc 1992 Feb; 24: 165-6
151. Mendez R, Aswad S, Khetan U, et al. Renal transplantation induction therapy - OKT3 vs MALG - outcome, cost [abstract]. Nephrol Dial Transplant 1995; 10 (6): 1069
152. Abramowicz D, Crusiaux A, Goldman M. Anaphylactic shock after retreatment with OKT3 monoclonal antibody. N Engl J Med 1992 Sep 3; 340: 736
153. Peces R, Urral JM, Escalada P, et al. High-dose methylprednisolone inhibits the OKT3-induced cytokine-related syndrome. Nephron 1993 Jan; 63: 118
154. Costanzo-Nordin MR. Cardiopulmonary effects of OKT3: determinants of hypotension, pulmonary edema, and cardiac dysfunction. Transplant ProC 1993 Apr; 25 Suppl. 1: 21-4
155. Bemelman FJ, Buysmann S, Surachno J, et al. Pretreatment with divided doses of steroids strongly decreases side effects of OKT3. Kidney Int 1994 Dec; 46: 1674-9
156. Jeyarajah DR, Thistlethwaite Jr JR. General aspects of cytokine-release syndrome: timing and incidence of symptoms. Transplant Proc 1993 Apr; 25 (2 Suppl. 1): 16-20
157. Abramowicz D, De Pauw L, Le Moine A, et al. Prevention of OKT3 nephrotoxicity after kidney transplantation. Kidney Int 1996; 49 Suppl. 53: S39-43
158. Shield III CF, Beilman G. Safety of OKT3 use in the operating room. Transplant Proc 1993 Apr; 25 (2 Suppl. 1): 43-4
159. Kupin W, Venkat KK, Ikemiyashiro D, et al. Morbidity of intraoperative OKT3 administration in primary cadaveric renal transplant recipients. Transplant Proc 1993 Feb; 25 (Pt 1): 572-4
160. Robinson ST. Administration of OKT3 in the operating room. Transplant Proc 1993 Apr; 25 (2 Suppl. 1): 41-2
161. Bolman III RM, Saffitz J. Early postoperative care of the cardiac transplantation patient: Routine considerations and immunosuppressive therapy. Prog Cardiovascular Dis 1990; 33: 137-48
162. Hayes MJ, Torzillo PJ, Sheil AGR, et al. Pneumocystis carinii pneumonia after liver transplantation in adults. Clin Transplant 1994 Dec; 8: 499-503
163. Hibberd PL, Tolkoff-Rubin NE, Conti D, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial. Ann Intern Med 1995 Jul 1; 123: 18-26
164. Rubin RH, Tolkoff-Rubin N, Minireview. Antimicrobial strategies in the care of organ transplant recipients. Antimicrob Ag Chemother 1993; 37: 619-24
165. Radhakrishnan J, Cohen D. Cytokine-release syndrome: General risk-factor modification - preparation of high-risk patients for use of OKT3. Transplant Proc 1993; 25 (2) Suppl. 1: 60-2
166. Abramowicz D, Pradier O, Marchant A, et al. Induction of thromboses within renal grafts by high-dose prophylactic OKT3. Lancet 1992 Mar 28; 339: 777-8
167. Woodle ES, Thistlethwaite Jr J, Emond JC, et al. OKT3 therapy for hepatic allograft rejection. Differential response in adults and children. Transplantation 1991 Jun; 51: 1207-12
168. Kehinde EO, Scriven SD, Feehally J, et al. Adverse effects of OKT3 therapy: increased risk with impaired renal function. Transplant Proc 1994 Aug; 26: 1945-7
169. Kehinde EO, Veitch PS, Scriven SD, et al. Complications of using OKT3 for induction of immunosuppression in recipients of kidneys from nonheart beating donors. Transplant Proc 1994 Dec; 26: 3123-5
170. Russ GR. Complications of immunosuppressive therapy in transplantation. 2: Specific immunosuppressive agents. Med J Aust 1992; 157: 264-7
171. Min DI, Monaco AP. Complications associated with immunosuppressive therapy and their management. Pharmacotherapy 1991; 11 (5): 119S-25S
172. Vasquez EM, Fabrega AJ, Pollak R. OKT3-induced cytokine-release syndrome: occurrence beyond the second dose and association with rejection severity. Transplant Proc 1995 Feb; 27: 873-4
173. Turner MC, Holman Jr JM. Late reactions during initial OKT-3 treatment. Clin Transpl 1993 Feb; 7 (Pt 1): 1-3
174. Kirklin JK, Naftel DC, Levine TB, et al. Cytomegalovirus after heart transplantation. Risk factors for infection and death: a multiinstitutional
175. Hibberd PL, Tolkoff-Rubin NE, Cosimi AB, et al. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 1992 Jan; 53: 68-72
176. Hooks MA, Perlino CA, Henderson JM, et al. Prevalence of invasive cytomegalovirus disease with administration of muromonab CD-3 in patients undergoing orthotopic liver transplantation. Ann Pharmacother 1992 Apr; 19 Suppl. 33: 617-20
177. Tejada F, Gomez E, Aguado S, et al. OKT3 treatment induces higher prevalence and greater severity of cytomegalovirus disease in renal transplant [abstract]. Kidney Int 1994 Aug; 46: 582
178. Johnson MR, Mullen GM, O'Sullivan EJ, et al. Risk/benefit ratio of perioperative OKT3 in cardiac transplantation. Am J Cardiol 1994 Aug 1; 74: 261-6
179. Bailey TC, Powderly WG, Storch GA, et al. Symptomatic cytomegalovirus infection in renal transplant recipients given either Minnesota antilymphoblast globulin (MALG) or OKT3 for rejection prophylaxis. Am J Kidney Dis 1993 Feb; 21: 196-201
180. Waser M, Maggiorini M, Lüthy A, et al. Infectious complications in 100 consecutive heart transplant recipients. Eur J Clin Microbiol Infect Dis 1994 Jan; 13: 12-8
181. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990 Dec 20; 323: 1723-8
182. Burtin P, Boman F, Pinelli G, et al. Cancers following thoracic organ transplantation: a single center study. Transplant Proc 1995 Apr; 27: 1765
183. Stempfle HU, Mudra H, Angermann CE, et al. Rapid growth of cutaneous neuroendocrine (Merkel cell) carcinoma during treatment of refractory cardiac allograft rejection with OKT3 monoclonal antibody. J Heart Lung Transplant 1993 May-Jun; 12: 501-3
184. Penn I. Cancers complicating organ transplantation. N Engl J Med 1990 Dec 20; 323: 1767-9
185. Reyes CV, Jensen J, Chinoy M. Pulmonary lymphoma in cardiac transplant patients treated with OKT3 for rejection: diagnosis by fine-needle aspiration. Diagn Cytopathol 1995 Feb; 12: 32-6
186. Rinde-Hoffman D, Cintron GB, Ferguson JE, et al. Lymphoproliferative disorder early after cardiac transplantation [published erratum appears in Am J Cardiol 1992 Mar 15;69(8):844]. Am J Cardiol 1991 Dec 15; 68: 1724-5
187. Morgan G, Superina RA. Lymphoproliferative disease after pediatric liver transplantation. J Pediatr Surg 1994 Sep; 29: 1192-6
188. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993 Dec 18-25; 342: 1514-6
189. Emery RW, Lake KD. Post-transplantation lymphoproliferative disorder and OKT3 [letter]. N Engl J Med 1991 May 16; 324: 1437
190. Hardy MA, Benvenisty AI, Cohen D, et al. Incidence of malignancies in renal and cardiac transplant recipients in relation to treatment with biologic agents. Clin Transplantation 1992; 6 Special issue: 269-71
191. Haverty TP, Sanders M, Carey G. A 2-year follow-up of post-transplantation malignancy in renal allograft recipients receiving muromonab-CD3 for immunosuppressive induction therapy. Drug Invest 1992; 4 (5): 403-8
192. Jones C, Bleau B, Buskard N, et al. Simultaneous development of diffuse immunoblastic lymphoma in recipients of renal transplants from a single cadaver donor: transmission of Epstein-Barr virus and triggering by OKT3. Am J Kidney Dis 1994 Jan; 23: 130-4
193. Cockfield SM, Preiksaitis JK, Jewell LD, et al. Post-transplant lymphoproliferative disorder in renal allograft patients. Clinical experience and risk factor analysis in a single center. Transplantation 1993 Jul; 56: 88-96
194. Canfield CW, Hudnall SD, Colonna JO, et al. Fulminant Epstein-Barr virus-associated post-transplant lymphoproliferative disorders following OKT3-therapy. Clin Transpl 1992 Feb; 6: 1-9
195. Ratkovec RM, O'Connell JB, Bristow MR, et al. Post-transplant lymphoproliferative disease in cardiac transplant patients receiving OKT3 therapy. Clin Transpl 1992 Jun; 6: 260-4
196. + B lymphocytes. Transplantation 1995 Feb 27; 59: 637-40
197. Bernstein D, Baum D, Berry G, et al. Neoplastic disorders after pediatric heart transplantation. Circulation 1993 Nov; 88 (Pt 2): 230-7
198. Lee CW, Logan JL, Zukoski CF. Cardiovascular collapse following orthoclone OKT3 administration: a case report. Am J Kidney Dis 1991 Jan; 17: 73-5
199. Hall KA, Dole EJ, Hunter GC, et al. Hyperpyrexia-related ventricular tachycardia during OKT3 induction therapy. Transplantation 1992 Dec; 54: 1112-3
200. Coleman AE, Norman DJ. OKT3 encephalopathy. Ann Neurol 1990 Dec; 28: 837-8
201. Marks WH, Perkal M, Bia M. Aseptic encephalitis and blindness complicating OKT3 therapy. Clin Transpl 1991 Dec; 5 (Pt 1): 435-8
202. Shihab FS, Barry JM, Norman DJ. Encephalopathy following the use of OKT3 in renal allograft transplantation. Transplant Proc 1993 Apr; 25 Suppl. 1: 31-4
203. Alegre M-L, Depierreux M, Florquin S, et al. Nephrotoxicity of anti-CD3 monoclonal antibodies [in French]. Nephrologie 1991; 12: 42-5
204. Batiuk TD, Bennett WM, Norman DJ. Cytokine nephropathy during antilymphocyte therapy. Transplant Proc 1993 Apr; 25 Suppl. 1: 27-30
205. First MR, SchroederTJ, Hariharan S. OKT3-induced cytokine-release syndrome: renal effects (cytokine nephropathy). Transplant Proc 1993 Apr; 25 Suppl. 1: 25-6
206. Dussol B, Brunet P, Vacher-Coponat H, et al. Haemolytic uraemic syndrome in a renal transplant recipient during OKT3 therapy. Nephrol Dial Transplant 1994; 9 (8): 1191-3
207. Doutrelepont J-M, Abramowicz D, Florquin S, et al. Early recurrence of hemolytic uremic syndrome in a renal transplant recipient during prophylactic OKT3 therapy. Transplantation 1992; 53: 1378-9
208. Bemelman FJ, Buysmann S, Yong SL, et al. Biphasic granulocytopenia after administration of the first dose of OKT3 [abstract]. Kidney Int 1995 Apr; 47: 1218
209. Burke III GW, Vercellotti GM, Simmons RL, et al. Reversible pancytopenia following OKT3. Use in the context of multidrug immunosuppression for kidney allografting. Transplantation 1989 Sep; 48: 403-7
210. Vasquez EM, Pollak R. Effect of OKT3 therapy on cyclosporine blood levels [abstract]. Pharmacotherapy 1995 Jan-Feb; 15: 118-9
211. Chan GL, Weinstein SS, Wright CE, et al. Encephalopathy associated with OKT3 administration. Possible interaction with indomethacin. Transplantation 1991 Jul; 52: 148-50
212. Doutrelepont JM, Abramowicz D, Borre B, et al. Prophylactic OKT3: practical considerations for the prevention of first-dose reactions. Transplant Proc 1993 Apr; 25 Suppl. 1: 45-6
213. Dantal J, Soulillou J-P. Use of monoclonal antibodies in human transplantation. Curr Opin Immunol 1991 Oct; 3: 740-7
214. Krensky AM, Clayberger C. Transplantation immunology. Pediatr Clin North Am 1994 Aug; 41: 819-39